Giuliana Grossi

Rachel Dalthorp, MD, discusses how zuranolone (Zurzuvae) can improve postpartum depression when compared with previous treatment approaches.

Results show that cognitive decline, combined with factors like smoking, obesity, and chronic health conditions, sharply increased the likelihood of premature death among patients with schizophrenia.

Chris Barton, LCSW, of Horizon Blue Cross Blue Shield of New Jersey, explores how the Youth Behavioral Health Strategy program focuses on addressing the specific needs of youth with mental health and substance use issues through a comprehensive approach.

The presidential debate showed the candidates’ differing views on women's health care, an area of medicine that currently faces issues related to patient care and outcomes as well as barriers to access.

From the presidential debate, ongoing conferences, and health care deserts in rural America, the Center on Health Equity & Access covers the latest news on population health, managed care, and health policy.

The National Comprehensive Cancer Network Policy Summit emphasized the importance of integrating diversity, equity, and inclusion into the oncology workforce to improve cancer care outcomes and address disparities while navigating legal and societal challenges.

New research reveals disparities in opioid prescribing by race among Medicare beneficiaries, sparking concerns about potential impacts on rehabilitation outcomes.

During the presidential debate, former President Donald Trump and Vice President Kamala Harris shared their differing visions for the future of the Affordable Care Act (ACA).

Ali Khawar, Employee Benefits Security Administration, US Department of Labor, believes the final rule will be a benefit to employers and health plans that are trying to do the right thing and offer robust mental health benefits or substance use benefits.

The Center on Health Equity & Access provides the latest news, research, and expert opinions on the state of equity in health care.

While psychedelics like LSD and psilocybin are generally well tolerated in clinical and research settings, study authors suspect inconsistent reporting of adverse events.

Lead investigators, presenters, and the chair of this year’s European Society of Cardiology Congress, John McMurray, MD, discussed the meeting highlights and recapped important data.

The FINEARTS-HF late-breaking data were forefront at the 2024 European Society of Cardiology Congress in London.

"Now we can actually focus and look at the disease itself, treat the heart disease itself, which is the plaque in the coronary arteries, as opposed to treating the risk of disease," Amir Ahmadi, MD, Mount Sinai, says in an interview at the European Society for Cardiology Congress.

Deepak Bhatt, MD, Mount Sinai Heart, highlights the kidney-specific outcomes of the pivotal EMPACT-MI clinical trial in an interview at the 2024 European Society of Cardiology Congress.

In patients with heart failure with mildly reduced and preserved ejection fraction, finerenone reduced the risk of heart failure worsening or hospitalizations compared with placebo, explained John McMurray, MD, the co–principal investigator of the FINEARTS-HF trial.

Christopher Kramer, MD, vice president of the American College of Cardiology, discusses the newest data on finerenone for heart failure presented during the FINEARTS Hot Line session at the European Society of Cardiology Congress.

Anna Mueller, MD, and Amir Ahmadi, MD, of Mount Sinai, highlight gaps in risk assessment tools for acute coronary syndrome, calling for more comprehensive screening strategies.

After moderating an emerging science session on acute ST-elevation myocardial infarction care, Dipti Itchhaporia, MD, American College of Cardiology, discussed the growing inclusivity in clinical trials through innovative digital tools and addressed the impact of GLP-1 therapies on cardiovascular treatment.

At the European Society of Cardiology (ESC) Congress 2024, attendees examine how cardiology practice evolves with access to new technology and innovative approaches.

In this interview, Sarah Manes, Global Liver Institute, explores the unique challenges faced by LGBTQI+ individuals, particularly those with disabilities, in accessing and receiving appropriate liver care.

Aetna has become the first major US insurer to expand access to fertility services by covering intrauterine insemination as a medical benefit for all eligible plans, marking a significant move toward greater equity in family-building options for people of all backgrounds.

Medicare has not clearly defined what constitutes "established cardiovascular disease," leading to variability in potential patient eligibility; therefore, researchers aimed to estimate the number of Medicare beneficiaries who would become newly eligible for semaglutide under different definitions.

New research reveals the first documentation of a significant rise in heat-related mortality rates in the US through 2023, contrasting with earlier studies that indicated a declining trend.

Martha Gulati, MD, Cedars-Sinai, discusses the topics expected to be featured at the European Society of Cardiology (ESC) Congress, including a debate she's participating in about the role of hormone replacement therapy (HRT) in primary cardiovascular disease prevention.

Brooke Kempf, PMHNP, from Indiana University Indianapolis, discusses the importance of timely outpatient care and how innovative approaches like long-acting injectables (LAIs) are helping to bridge the gap in treatment for schizophrenia.

Learn more about the negotiated Medicare drug prices and what the FDA's rejection of therapeutic MDMA means for mental health care through expert reactions. Other highlights include pharmacy-based HIV care, gaps in care for gastrointestinal stromal tumors, and the obesity epidemic.

The growing utilization of long-acting injectable (LAI) medications for treating patients with schizophrenia indicates a positive trend in mental health practice, according to Brooke Kempf, PMHNP, Indiana University Indianapolis.

The FDA's decision to reject midomafetamine (MDMA) capsules in combination with assisted psychotherapy (MDMA-AT) for adults with PTSD reignited the controversial conversation around investigative psychedelic therapy.

Health equity news appearing in the August issue of Evidence-Based Oncology.